Jiangsu Recbio Technology Co., Ltd. engages in the research and development of vaccines. The company is headquartered in Taizhou, Jiangsu and currently employs 507 full-time employees. The company went IPO on 2022-03-31. The firm is still in the research and development stage. The firm's vaccine pipeline includes recombinant human papillomavirus (HPV) 9-valent vaccine, novel adjuvanted recombinant HPV 9-valent vaccine, recombinant HPV bivalent (Types 16/18) vaccine, recombinant HPV bivalent (Types 6/11) vaccine, novel adjuvanted recombinant HPV quadrivalent vaccine, novel adjuvanted recombinant shingles vaccine, novel adjuvanted recombinant respiratory syncytial virus vaccine, recombinant metapneumovirus vaccine, recombinant human cytomegalovirus vaccine, recombinant bicomponent COVID-19 vaccine, recombinant hepatitis B virus vaccine, and others.
02179.HK stock price ended at $4.94 on 星期四, after rising 0.00%
On the latest trading day Feb 12, 2026, the stock price of 02179.HK rose by 0.00%, climbing from $4.94 to $4.94. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $4.94 and a high of $4.94. Alongside this price increase, trading volume also rose by 22.0K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, -- shares were traded, amounting to a market value of approximately $1.5B.